Avicena Group Inc., a late stage biotechnology company focused on commercialising its proprietary cellular energy modulation technology, announced that the US Patent and Trademark Office (USPTO) has issued US Patent No 7,186,754, entitled, "Use of Creatine or Creatine Compounds for Skin Preservation,"
The newly issued patent contains claims which cover methods and compositions for treating uneven skin pigmentation using a topical application of creatine and carnitine. This patent enhances the company's skin care patent portfolio, which also contains US Patent No. 6,242,491, with claims directed to methods for treating skin damage resulting from sun radiation, stress, fatigue or free radicals by administering creatine.
"We are extremely pleased to have received this additional patent claim to broaden our IP position in dermaceuticals," stated Dr Belinda Tsao-Nivaggioli, Avicena's CEO.
Dr Tsao-Nivaggioli continued, "The discovery that a composition of creatine and carnitine is an effective treatment for uneven skin pigmentation provides a new approach to a very common dermatological problem."
Avicena Group Inc. is a late stage biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes.